Market Data Current As Of: September 12, 2026
Related Competitor Intelligence
Compare market positioning with top industry peers
Explore Cencora
Core profile pages, annual revenue records, and related research hubs for this company.
Compare market positioning with top industry peers
Explore Cencora
Core profile pages, annual revenue records, and related research hubs for this company.
Financial Performance
Revenue
$321.3B
Market Cap
$45.1B
Net Income
$1.6B
Employees
46,000
Cencora (formerly AmerisourceBergen) operates as an indispensable, heavily consolidated node in global healthcare logistics. Under CEO Steven H. Collis, the drug distribution giant generated a staggering $275.4 billion in revenue and maintains a $45.1 billion market cap with exactly 46000 employees. Cencora's top-line growth in 2026 is almost entirely fueled by the unprecedented distribution volumes of specialty pharmaceuticals and GLP-1 weight-loss drugs. Operating in a regulated oligopoly alongside McKesson and Cardinal Health Cencora is acquiring smaller, specialized European logistics firms to expand its higher-margin animal health and international biosimilar distribution networks to offset razor-thin domestic margins.
Revenue Trend Analysis
YoY Change
+9.3%
3-Year CAGR
+10.4%
Peak Year
2025
Trend
Consistent Growth
Cencora, Inc. has reported revenue across 4 fiscal years, compounding at +10.4% annually over 3 years. The most recent year saw a 9.3% increase versus the prior year. Revenue peaked in 2025 at $321.3B. Out of 3 reported periods, 3 showed growth and 0 showed a decline.
| Fiscal Year | Revenue | Net Income | YoY Change |
|---|---|---|---|
| FY2025 | $321.3B | $1.6B | +9.3% |
| FY2024 | $294.0B | — | +12.1% |
| FY2023 | $262.2B | — | +9.9% |
| FY2022 | $238.6B | — | — |
Source: SEC EDGAR filings, annual earnings releases, and verified financial disclosures.
Click any row to see year details.
Cencora, Inc. reported approximately $275.4B in fiscal year 2025 with a team of 46,000 employees worldwide.
Cencora, Inc. strategically balances reinvestment into core R&D with operational cost discipline, focusing on workflow automation to expand operating margins in 2026.
Financial performance in Healthcare Distribution and Specialty Pharmacy is driven by steady cash generation and pricing power, enabling Cencora, Inc. to reinvest in high-return strategic initiatives.
Using these figures? Please credit CorpDigest with a link.
CorpDigest. "Cencora, Inc. Revenue & Financials." CorpDigest, https://corpdigest.com/company/cencora/financials.<div style="font-family:system-ui,sans-serif;font-size:14px;line-height:1.5;border:1px solid #e2e8f0;border-radius:8px;padding:12px 16px;max-width:520px"><strong>Cencora, Inc. reported $321B in revenue (FY2025).</strong><br>Source: <a href="https://corpdigest.com/company/cencora/financials" target="_blank" rel="noopener">CorpDigest — Cencora, Inc. financials</a></div>